Prospective Real-World Study of Multimodal AI
NCT07269236
Pancancer
Guangzhou, Guangdong, China
View Trial DetailsNCT Number: NCT07157618
Histopathology remains the gold standard for disease diagnosis, yet faces challenges including pathologist shortages and diagnostic model limitations. This underscores the critical need to develop deep learning-based pathology foundation models integrating prospective imaging and clinical data. Such models would enhance diagnostic accuracy and efficiency, enabling tumor grading, histo-molecular classification, and intelligent chemotherapy guidance - ultimately optimizing clinical workflows. However, a critical gap remains: the absence of prospectively validated, pan-disease pathology foundation models. Developing clinically validated models is therefore imperative.
Interested in participating?
Request Info18 year–75 year
All sexes
Observational
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
1.Patients with missing data or specimens not meeting quality control requirements for analysis.
Time frame: Diagnostic evaluation will be performed within 1 week when the WSIs are obtained
Area under the curve
Time frame: Diagnostic evaluation will be performed within 1 week when the WSIs are obtained
The true negative rate (TNR) of the diagnostic platform, which is the ratio between the number of negative individuals correctly categorized by platform and the total number of actual negative individuals (%).
Time frame: Diagnostic evaluation will be performed within 1 week when the WSIs are obtained
The true positive rate (TPR) of the diagnostic platform, which is the ratio between the number of positive individuals correctly categorized by platform and the total number of actual positive individuals (%).
Contact information is provided by the study sponsor or research team.
Nanfang Hospital, Southern Medical University
Other
Development and Clinical Application of Deep Learning-Based Prospective Pathology Foundation Models
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07269236
Pancancer
Guangzhou, Guangdong, China
View Trial DetailsNCT07239297
Pancancer
Guangzhou, Guangdong, China
View Trial Details